Lars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer (CQCO). Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality.
Lars brings 20 years of experience in the Biotech and Pharmaceutical industry in the Quality, Manufacturing, Product Safety and Regulatory Affairs areas.
"We are delighted to welcome Lars to Sobi", said Geoffrey McDonough, President and CEO at Sobi. "Sobi has been expanding the scope and geographic area of operations and the demands and complexity of external regulations governing our business has also increased. Lars will sustain and deepen our global commitment to quality in all aspects of our work, and will be a valuable addition to our senior leadership team."
"I'm very much looking forward to joining the team at Sobi and to entering my new role - developing and delivering therapies at the highest level of quality to people living with a rare disease," said Lars Dreiøe.
Lars will join Sobi on 18 January 2016.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
|E: email@example.com||E: firstname.lastname@example.org|
The above information was released for public distribution on 21 December 2015, at 08:00 CET.